Risk of kidney injury following oral phosphosoda bowel preparations

Journal of the American Society of Nephrology

Volumn 18, Issue 12, 2007, Pages 3199-3205

  Brunelli, Steven M ^a,b   Lewis, James D ^a   Gupta, Meera ^a   Latif, Sherif M ^a   Weiner, Mark G ^a   Feldman, Harold I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Center for Clinical Epidemiology and Biostatistics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INORGANIC SALT; ORAL SODIUM PHOSPHOSODA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; COLONOSCOPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INTESTINE PREPARATION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; SENSITIVITY ANALYSIS;

EID: 36849040635     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007040440     Document Type: Article

References (29)

1. Seeff LC, Richards T, Shapior JA, Nadel MR, Manninen DL, Given LS, Dong FB, Winges LD, McKenna MT: How many endoscopies are performed for colorectal cancer screening? Results from CDCs survey of endoscopic capacity. Gastroenterol 127: 1670-1677, 2004
2. Hsu CW, Imperiale TF: Meta-analysis and cost comparison of polyethylene glycol lavage versus sodium phosphate for colonoscopy preparation. Gastrointest Endosc 48: 276-282, 1998
3. Tan JJ, Tjandra JJ: Which is the optimal bowel preparation for colonoscopy: A meta-analysis. Colorectal Dis 8: 247-258, 2006
4. Belsey J, Epstein O, Heresbach D: Systematic review: Oral bowel preparation for colonoscopy. Aliment Pharmacol Ther 25: 373-384, 2007
5. Orias M, Mahnensmith RL, Perazalla MA: Extreme hyperphosphatemia and acute renal failure after a phosphorus-containing bowel regimen. Am J Nephrol 19: 60-63, 1999
6. Ullah N, Yeh R, Ehrinpreis M: Fatal hyperphosphatemia from a phosphosoda bowel preparation. J Clin Gastroenterol 34: 457-458, 2002
7. Fine A, Patterson J: Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: Two cases and review of the literature. Am J Kidney Dis 29: 103-105, 1997
8. Markowitz GS, Stokes MB, Radhakrishnan J, D'Agait VD: Acute phosphate nephropathy following oral sodium phosphate bowel purgative: An underrecognized cause of chronic renal failure. J Am Soc Nephrol 16: 3389-3396, 2005
9. Chan A, Depew W, Vanner S: Use of oral sodium phosphate colonic lavage solution by Canadian colonoscopists: Pitfalls and complications. Can J Gastroenterol 11: 334-338, 1997
10. lbels LS, Alfrey AC, Haut L, Huffer WE: Preservation of function in experimental renal disease by dietary restriction of phosphate. N Engl J Med 298: 122-126, 1978
11. Karlinsky ML, Haut L, Buddington B, Schrier NA, Alfrey AC: Preservation of renal function in experimental glomerulonephritis. Kidney Int 17: 293-302, 1980
12. Cozzolino M, Dusso AS, Liapis H, Finch J, Lu Y, Burke SK, Slatopolsky E: The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J Am Soc Nephrol 13: 2299-2308, 2002
13. Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wadad M: Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant 18: 2014-2023, 2003
14. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, Lacher DA, Hostetter TH: Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16: 180-188, 2005
15. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
16. Zager R: Hyperphosphatemia: A factor that provokes severe experimental acute renal failure. J Clin Lab Med 53: 2425-2429, 1982
17. Cadman EC, Lindberg WR, Bertino JR: Hyperphosphatemia and hypocalcaemia accompanying rapid cell lysis in a patient with Burkitt's lymphoma and Burkitt cell leukemia. Am J Med 62: 283-290, 1977
18. Ettinger DS, Harker WG, Gerry WH, Sanders RC, Sarai R: Hyperphosphatemia, hypocalcemia and transient renal failure. JAMA 239: 2472-2474, 1978
19. Kanfer A, Richet G, Roland J, Chatelet F: Extreme hyperphosphatemia causing acute anuric nephrocalcinosis in lymphosarcoma. BMJ 1: 1320-1321, 1979
20. Boles JM, Dutel JL, Briere J, Mialon P, Robasckiewicz M, Garre M, Briere J: Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer 53: 2425-2429, 1984
21. Alfrey AC: The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int 90: S13-17, 2004
22. Ritz E, Gross ML, Dikow R: Role of calcium-phosphate disorders in the progression of renal failure. Kidney Int 99: S66-70, 2005
23. Loghman-Adham M: Role of phosphate retention in the progression of renal failure. J Lab Clin Med 122: 16-26, 1993
24. Habr-Gama A, Bringel RW, Nahas SC, Araujo SE, Souza Junior AH, Calache JE, Alves PA: Bowel preparation for colonoscopy: Comparison of mannitol and sodium phosphate. Results of a prospective randomized study. Rev Hosp Clin Fac Med Sao Paulo 54: 187-192, 1999
25. DiPalma JA, Buckley SE, Warner BA, Culpepper RM: Biochemical effects of oral sodium phosphate. Dig Dis Sci 41: 749-753, 1996
26. Lieberman DA, Ghormlet J, Flora K: Effects of oral sodium phosphate colon preparation on serum electrolytes in patients with normal serum creatinine. Gastrointest Endosc 43: 467-469, 1996
27. Hoenig JM, Heisey DM: The abuse of power: The pervasive fallacy of power calculations for data analysis. Am Stat 55: 19-24, 2001
28. Pearce N: What does the odds ratio estimate in a case-control study? Int J Epidemiol 22: 1189-1191, 1993
29. Cornfield J: A method of estimating comparative rates from clinical data: Applications to cancer of the lung, breast and cervix. J Natl Cancer Inst 11: 1269-1275, 1951